124289-24-3

Basic information

• Product Name: 3-Bromo-5-cyanobenzyl bromide
• Synonyms: 3-Bromo-5-cyanobenzyl bromide;3-Bromo-5-(bromomethyl)benzonitrile
• CAS NO: 124289-24-3
• Molecular Formula: C₈H₅Br₂N
• Molecular Weight: 274.94
• Mol File: 124289-24-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-Bromo-5-cyanobenzyl bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-cyanobenzyl bromide(124289-24-3)
• EPA Substance Registry System: 3-Bromo-5-cyanobenzyl bromide(124289-24-3)

Safety Data

• Hazardous Substances Data: 124289-24-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-cyanobenzyl bromide is used as a reagent for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure allows for the creation of a wide range of chemical compounds with potential medicinal properties.
Used in Agrochemical Industry:
3-Bromo-5-cyanobenzyl bromide is also utilized in the synthesis of agrochemicals, serving as a key component in the development of pesticides and other agricultural chemicals that help protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
As a versatile building block, 3-Bromo-5-cyanobenzyl bromide is employed in organic synthesis for the preparation of diverse chemical compounds. Its presence in various chemical reactions enables the production of a broad spectrum of organic molecules with different applications across various industries.
Safety and Storage:
Due to its reactivity, 3-Bromo-5-cyanobenzyl bromide should be handled with care and stored in a cool, dry place away from sources of ignition to prevent any potential hazards. Proper safety measures and precautions are essential when working with this chemical compound.

Upstream product

• 124289-21-0 3-bromo-5-methylbenzonitrile 
• 556-96-7 5-bromo-1,3-xylene 
• 58530-13-5 3-bromo-5-methyl-benzoic acid 
• 51719-69-8 1-bromo-3-(bromomethyl)-5-methylbenzene 
• 648439-19-4 (3-bromo-5-methylphenyl)methanol 
• 1007578-82-6 3-bromo-5-methylbenzamide 

Downstream Products

• 1177558-49-4 3-bromo-5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]benzonitrile 
• 1214320-05-4 C₁₀H₇BrN₄ 
• 1331750-43-6 tert-butyl 2-(N-(3-bromo-5-cyanobenzyl)-2,2-dimethylchroman-6-sulfonamido)acetate 
• 1383985-28-1 3-bromo-5-(methoxymethyl)benzonitrile 
• 1177558-50-7 3-(aminomethyl)-5-bromobenzonitrile 
• 1177558-71-2 tert-butyl (3-bromo-5-cyanobenzyl)carbamate 

Relevant articles and documents

TYK2 INHIBITORS AND USES THEREOF

Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors

Neuronal nitric oxide synthase (nNOS) inhibition is a promising strategy to treat neurodegenerative disorders, but the development of nNOS inhibitors is often hindered by poor pharmacokinetics. We previously developed a class of membrane-permeable 2-amino

PYRIDONE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

The present invention relates to 2-pyridone derivatives of Formula (I) or (IV) as herein described, compositions containing such compounds, synthetic processes for making such compounds, and therapeutic methods that include the administration of such comp

Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template

Single agents against multiple drug targets are of increasing interest. Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS). The aromatase inhibitory pharmacophore was thus introduced into a known biphenyl STS inhibitor to give a series of novel dual aromatase-sulfatase inhibitors (DASIs). Several compounds are good aromatase or STS inhibitors and DASI 20 (IC50: aromatase, 2.0 nM; STS, 35 nM) and its chlorinated congener 23 (IC50: aromatase, 0.5 nM; STS, 5.5 nM) are examples that show exceptional dual potency in JEG-3 cells. Both biphenyls share a para-sulfamate-containing ring B and a ring A, which contains a triazol-1-ylmethyl meta to the biphenyl bridge and para to a nitrile. At 1 mg/kg po, 20 and 23 reduced plasma estradiol levels strongly and inhibited liver STS activity potently in vivo. 23 is nonestrogenic and potently inhibits carbonic anhydrase II (IC50 86 nM). A complex was crystallized and its structure was solved by X-ray crystallography. This class of DASI should encourage further development toward multitargeted therapeutic intervention in HDBC.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.